Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan’s Autor-de-Force Move into Quality “Differentiation” and Sterile Injectables

This article was originally published in RPM Report

Executive Summary

Mylan is investing heavily to create a competitive advantage based on manufacturing quality – and public policy. The firm’s recruitment of FDA’s Deborah Autor highlights a strategy to spend more on quality while aiming at higher margins, especially in sterile injectables where the company sees an opening after widespread quality breakdowns across the industry.


Related Content

Culture Clash: U.S. FDA Tries to Re-educate Indian Firms on Processes And Accurate Reporting
Culture Clash: FDA Tries to Re-Educate Indian Firms on Processes and Accurate Reporting
After A Brief Pause, Injectables Cash Cow Agila Is Back Into Production; Pfizer Expects Shipping To Commence Soon
FDA’s Autor Moves To Mylan: Company’s Gain May Also Be Company’s Loss
Growing Pains for Generic Drugs: OGD Gains Respect, But Loses Geba
GDUFA Implementation Will Be Overseen By Mylan’s Representative in the House


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts